前列腺切除及放疗后前列腺床局部复发的挽救性高强度聚焦超声:初步结果
单中心回顾性分析22例根治性前列腺切除及辅助或挽救性放疗后前列腺床局部复发的前列腺癌患者,接受挽救性高强度聚焦超声治疗。中位随访2.32年,3年无治疗失败生存率49.7%、无进展生存率60.4%,50%患者PSA最低值≤0.2 ng/ml且与更好生存显著相关,但27.3%发生III级并发症。
要点
- 挽救性HIFU对前列腺床局部复发者3年无治疗失败生存率49.7%、无进展生存率60.4%。
- PSA最低值≤0.2 ng/ml者无治疗失败和无进展生存概率显著更优。
- 吻合口周围复发者II-III级尿失禁发生率显著高于膀胱后复发。
核心结论
- 对根治性前列腺切除及挽救性放疗后前列腺床局部复发的前列腺癌,挽救性高强度聚焦超声显示鼓舞人心的肿瘤学结果,但并发症发生率较高。
主要发现
- 3年无治疗失败生存率估计为49.7%,无进展生存率估计为60.4%。
- 50%患者达到PSA最低值≤0.2 ng/ml,该最低值与更好的无治疗失败生存(p=0.003)和无进展生存(p=0.037)显著相关。
- 6例(27.3%)发生III级并发症。
- 吻合口周围复发者II-III级尿失禁发生率为36.4%,膀胱后复发者为0%,差异显著(p=0.027)。
关键数值与推荐
- 治疗失败定义为前列腺床持续或复发性前列腺癌和/或转移和/或开始全身治疗。
- 进展定义为转移和/或开始全身治疗。
- 并发症采用Clavien-Dindo分类评估,控尿采用Ingelman-Sundberg评分评估。
临床怎么用
- 对于根治性前列腺切除及放疗后前列腺床局部复发且经胆碱PET、多参数MRI和经直肠活检确认的患者,可考虑挽救性HIFU。
- 治疗后PSA最低值≤0.2 ng/ml与更好的肿瘤学结局相关,可作为疗效监测参考。
- 吻合口周围复发者尿失禁风险较高,选择治疗时应充分评估并告知。
局限性
- 回顾性单中心设计,样本量小(22例),随访时间较短(中位2.32年)。
- 结果为初步报告,需更大样本和更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to report the preliminary results of salvage high-intensity focused ultrasound for locally recurrent prostate cancer in the prostatic bed after radical prostatectomy and adjuvant or salvage radiotherapy. MATERIALS AND METHODS: We retrospectively analyzed a single-center cohort of men treated with salvage high-intensity focused ultrasound for locally recurrent prostate cancer after radical prostatectomy and adjuvant or salvage radiotherapy. All patients had a combination of choline positron emission tomography, multiparametric magnetic resonance imaging, and transrectal biopsies to confirm the local recurrence. Treatment failure was defined as persistent or recurrent prostate cancer in the prostatic bed and/or metastasis and/or introduction of systemic treatment. Progression was defined as metastasis and/or introduction of systemic treatment. Complications (Clavien-Dindo classification) and continence (Ingelman-Sundberg score) were evaluated. Kaplan-Meier analysis estimated oncological outcomes. RESULTS: Between July 2009 and November 2018, 22 patients were included; the median followup was 2.32 years. At 3 years, treatment failure-free survival rate was estimated to be 49.7% and progression-free survival rate 60.4%. Prostate specific antigen nadir ≤0.2 ng/ml was reached in 50% of the patients. A nadir of ≤0.2 ng/ml was significantly associated with better treatment failure-free and progression-free survival probabilities (p=0.003 and p=0.037, respectively). Grade III complications occurred in 6 patients (27.3%). Onset of grade II-III incontinence was significantly more frequent in cases of perianastomotic (36.4%) compared to retrovesical recurrence (0%; p=0.027). CONCLUSIONS: Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after radical prostatectomy and salvage radiotherapy showed encouraging oncological results despite significant morbidity. The perianastomotic recurrence was linked to a higher risk of incontinence.
引用
- Khedime S, Gelet A, Rouvière O, et al. Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results. J Urol. 2021. PMID: 33835863. doi:10.1097/JU.0000000000001771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。